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Heart failure (HF) is one of the most common reasons for hospitalization and the leading 
cause of 30-day readmissions. There is great interest in developing strategies to reduce 
hospital utilization in this large and growing patient population. Aside from classic heart 
failure symptoms of dyspnea and fatigue, other symptoms reported include decreased 
appetite, pain and anxiety. These symptoms may be amenable to treatment and patients 
hospitalized with heart failure may benefit from intensive symptom management in the 
form of palliative care. There is limited data in the heart failure population about 
symptom burden both during hospitalization and shortly after hospital discharge, as well 
as patients’ perceptions of palliative care. Therefore, our aim was to evaluate if patients 
discharged from the hospital after acute decompensated heart failure exhibit a high 
burden of residual symptoms one week post-discharge. Patients hospitalized for heart 
failure were enrolled in this prospective cohort study. Patients were interviewed about 
symptom burden using the Edmonton Symptom Assessment System (ESAS) and Patient 
Health Questionnaire (PHQ-8) during the hospital admission and 7 to 10 days post-
discharge. Patients were also questioned about existing knowledge of palliative care, and 
then - after a brief, standardized explanation of the goals of palliative care - patients were 
queried about their interest in receiving palliative care services. Ninety-one patients were 
enrolled; their mean age was 71.5 years (SD 12.6 years) 51.6% were female and 74.5% 
had NYHA class III/IV heart failure.  Symptoms frequently reported during the baseline 
interview included decreased wellbeing (94.1%), fatigue (85.9%), shortness of breath 
(81.2%), anxiety (62.4%) and pain (47.1%). Frequent symptoms reported in the follow-
up interview were decreased wellbeing (95.3%), fatigue (88.2%) and shortness of breath 
(84.7%), anxiety (60.0%) and pain (55.3%). While only 22.4% of patients had heard of 
‘palliative care,’ after a standardized explanation, 68.2% were interested in receiving 
palliative care services while hospitalized. Patients hospitalized for heart failure 
experience a high burden of symptoms, including not only those usually associated with 
heart failure such as dyspnea and fatigue, but also anxiety and pain. These symptoms are 
common during hospitalization and the majority of patients appear to experience 
troublesome symptoms shortly after discharge as well. Given that patients’ symptoms 
frequently drive health care utilization, integration of palliative care into routine heart 
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Introduction 
Heart failure is a common and costly condition. As the population of the 
United States has aged and survival with cardiovascular disease has increased, the 
number of people with heart failure has also increased considerably over the past 20 
years (1). This highly prevalent disease affects patients and families, and also poses a 
public health concern. An estimated 5.1 million people in the United Stations suffer 
from heart failure, with 825,000 new diagnoses, 1,000,000 hospitalizations and 
676,000 visits to the emergency department annually (2). Patients hospitalized for 
heart failure experience the highest rates of early readmissions; approximately 
twenty-five percent of those hospitalized with heart failure are readmitted within 
thirty days and half readmitted within 6 months (3). Furthermore, the 1-year 
mortality after hospitalization for heart failure is 30% and median life expectancy is 
less than five years (4). This poses a considerable economic burden that health 
systems are under increasing pressure to curtail (5, 6). The total cost of heart failure 
is driven largely by hospitalizations and was estimated to be $30.7 billion in 2012, 
with a projected increase to $69.7 billion by 2030 (7).  
 
Heart Failure: An Overview  
 The American Heart Association (AHA)/American College of Cardiology 
guidelines define heart failure as “a complex clinical syndrome that can result from 
any structural or functional cardiac disorder that impairs the ability of the ventricle to 
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fill or eject blood” (8). Pump failure leads to inadequate blood flow to maintain 
oxygenation requirements. Etiologies include coronary artery disease, hypertension, 
valvular heart disease, genetic disorders, arrhythmias, infiltrative disorders, viruses, 
and cardiomyopathies. Various methodologies have been proposed for diagnosing 
heart failure, including the Framingham criteria, Boston criteria and the European 
Society of Cardiology criteria. As a clinical syndrome, heart failure is a clinical 
diagnosis based on various signs (edema, rales, jugular venous distention, pleural 
effusion, pulmonary edema, displaced point of maximal impulse, S3) and symptoms 
(dyspnea, fatigue, cough, paroxysmal nocturnal dyspnea, orthopnea, ascites) (9). 
This chronic disease is characterized by acute decompensations, or worsening 
of the symptoms of disease. Treatment for acute decompensated heart failure includes 
correcting underlying causes (i.e., arrhythmias, valvular disease, etc.), assuring 
adequate oxygenation and ventilation, administrating intravenous diuresis for fluid 
removal with loop and thiazide diuretics, restricting sodium and fluid, and vasodilator 
therapy (8).  
 An estimated 5.1 million people in the United Stations suffer from heart 
failure and the prevalence rises with age, affecting 6-10% of the population aged 65 
years of age or older (8). The Rotterdam study, a prospective cohort study of 
inhabitants of a suburb of Rotterdam in the Netherlands, found that the prevalence of 
heart failure increased with age, from 0.9% in those aged 55-64 to 17.4% in those 85 
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years or older and estimated that 30% of people 55 years of age or older will develop 
heart failure (10). The Framingham study found that the prevalence of heart failure in 
men increases to 66 per 1000 at 80-89 years of age from 8 per 1000 at 50-59 years of 
age, and increases 70 per 1000 at 80-89 years of age from 8 per 1000 at 50-59 years 
of age in women (11). A recent large study of three million Medicare beneficiaries 
aged 65 years or older in the United States found that while the incidence of heart 
failure decreased from 1994-2003, the prevalence increased from steadily from 
approximately 140 000 to 200 000.  
This highlights that the increased burden of the disease is not related to 
increased incidence in this population. The increased prevalence is due to the aging 
population as well as better survival from coronary heart disease such as myocardial 
infarctions and valvular heart disease. The population of patients 65 years of age or 
older in the United States is predicted to increase from 39.6 million in 2009, 
representing 12.9% of the population, to 72.1 million by 2030, representing 19% of 
the population (12). Thus there will an increase in the prevalence of heart failure over 
the next few decades. Improvements in primary cardiovascular prevention, including 
control of hypertension and hyperlipidemia, implementation of secondary prevention 
therapies such as usage of aspirin and beta-blockers and increasing use of 
percutaneous coronary intervention have translated into improved outcomes after 
acute myocardial infarction hospitalizations (13-20). 
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Symptom Burden in Heart Failure  
Although improvements in therapies have decreased mortality rates in the last 
decades for heart failure patients (21), current guideline based therapies are not 
curative.  Heart failure remains a fatal chronic and progressive disease, eventually 
characterized by multi-organ involvement, persistent symptoms and recurrent 
decompensations leading to hospitalizations. The conventional clinical approach to 
patients requiring hospitalization for decompensated heart failure focuses on 
improving signs of congestion and optimizing fluid status (8, 22). Objective data, 
such as body weight and oxygenation, are typically used to assess improvement in 
clinical status and patients’ readiness for hospital discharge (22). However, it is 
increasingly recognized that patients with heart failure suffer from a range of 
symptoms. Aside from classic heart failure symptoms, such as dyspnea and edema, 
previous studies have shown that patients with heart failure often experience pain, 
anorexia, anxiety and depression (23-26). Dyspnea, fatigue and edema are the focus 
of treatment but symptoms of pain, anorexia, anxiety and depression may be 
amenable to palliation. 
Previous studies have documented a high prevalence of symptoms not 
classically associated with heart failure. Small scale studies have described the 
prevalence of pain in those hospitalized for heart failure ranging from 60-85% (26-
28) and between 52-84% in the outpatient setting (29, 30). Possible causes for pain in 
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these patients include impaired circulation and oxygenation, neurohormonal 
derangements and changes in sensation and neurological conduction (25). There has 
been little research done localizing sites of pain, but one survey of 349 patients with 
heart failure found that patients’ common sources of pain include chest pain, leg pain 
and joint pain (28).  
Depression is prevalent in this population as well, between 20-36% of those 
hospitalized for heart failure have met the DSM-V criteria for major depression (31-
34).  Heart failure patients with depression have increased fatigue and other 
symptoms (35) and have been shown to have worse outcomes (35, 36). Similarly, 
high levels of anxiety have been associated decreased quality of life in these patients 
(37). Furthermore, heart failure patients are an increasingly aging population whose 
disease burden is complicated by comorbidities, polypharmacy, and functional status 
that may contribute to the complexity of symptoms experienced (38). Traditional 
evidence-based guidelines for management of hospitalizations treat overt signs of 
heart failure but they do not fully address the complex signs and symptoms 
experienced by heart failure patients. These physical and psychosocial symptoms 
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Role of Palliative Care in Heart Failure  
One strategy to improve care for these patients is to integrate palliative care 
into heart failure disease management (39, 40). Palliative care was initially available 
as hospice based therapy for cancer patients who are not receiving curative treatments 
starting in the 1970s (41). It is now being integrated into many chronic diseases and 
has grown to a non-hospice model based on patient and family needs regardless of 
prognosis (42). Palliative care is a multidisciplinary and holistic approach with the 
goal of alleviating suffering and increasing the quality of life for patients and families 
with advanced disease by focusing on symptom management, communication, 
psychosocial support and coordination of care (43). Palliative care is not provided 
because patients are at the end of life, it is offered concurrently with medical 
treatment.  It provides an additional layer of support to help patients cope with and 
navigate the impact of serious illness by addressing both patients’ and families’ 
physical, emotional, spiritual, and logistical needs (42). This is particularly relevant 
for older patients with heart failure, who face an ever-expanding array of invasive 
therapies, including implantable cardioverter defibrillators (ICDs), valve repair, and 
ventricular assist devices. 
There have been numerous calls to include palliative care as a component of 
heart failure management, including from the American Heart Association, but fewer 
than 10% of patients with heart failure receive palliative care (44, 45). A survey of 
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members of the Heart Failure Society of America found that 67% majority of the 
physicians had not referred patients to palliative care services (46). While there is 
evidence that palliative care can improve patients’ symptoms and satisfaction while 
reducing costs and health care utilization and even extending life (47-51) most of this 
research was done in cancer patients. There are important differences between 
patients with cancer and those with heart failure, making direct extrapolation of 
findings on the use of palliative care from oncology to heart failure difficult. Notably, 
patients with heart failure have a less predictable trajectory than cancer patients and it 
is often not clear which exacerbation with lead to death. Their course is marked by 
exacerbations characterized by a rapid decline in function; and although with 
appropriate treatments some may improve clinically, the overall course remains a 
downward trajectory (52, 53). This variable trajectory is a barrier for hospice referral 
and thus the non-hospice model of palliative care is better suited in the heart failure 
patient population.  
The physical and psychological symptoms that heart failure patients 
experience are similar to that of cancer patients. One cross sectional study of 60 
patients with symptomatic heart failure and 30 patients with malignancy found that 
both groups and similar numbers of physical symptoms, depression scores and 
spiritual well being, even after adjusting for demographic factors and severity of heart 
failure (54). Another cross sectional study of 50 heart failure patients and 50 cancer 
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patients found no statistical difference between symptom burden, emotional well 
being and quality of life scores between the two groups (55). A small survey of 
twenty patients with heart failure age 60 years of older reported symptom experience 
similar to cancer patients, such as extreme fatigue, difficulty with activities of daily 
living, etc. and none had access to palliative care (56). These findings highlight that 
palliative care has strong potential to be beneficial in patients with heart failure just as 
it is in patients with cancer.  
Palliative care can increase quality of life alleviating symptoms that are not 
targeted by current guidelines. For example, current guidelines suggest appropriate 
dosing of loop diuretics to relieve pulmonary congestion, whish also improves both 
dyspnea and exercise capacity (57). In contrast, a palliative care assessment 
recommends oral opioids as treatment for pain in heart failure which may also 
improve dyspnea, and benzodiazepines for alleviating anxiety as well as associated 
dyspnea (58). Musculoskeletal pain can also be targeted with non-pharmacologic 
treatments such as exercise, heat/cold treatments and joint injections (23). 
A palliative care assessment for heart failure recommends evaluating fatigue 
broadly as it would for a patient without heart failure, with a workup to rule out 
causes such as anemia, dehydration, depression, thyroid dysfunction, electrolyte 
abnormalities etc. (59). Patients should also be screened for depression and treated 
appropriately (psychotherapy, pharmacologic treatment such as SSRIs if indicated).  
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  Aside from robust symptom assessment and management, a core component 
of palliative care is communication about goals of care. Data from other groups 
demonstrate that there is a need for better communication in patients with heart 
failure (60-63).  For instance, a study focusing on communicating with heart failure 
patients found that majority of hospitalized patients wanted more information on 
disease management and prognosis, and did not recall conversations regarding end of 
life during their hospital stay (63). A systematic literature review of studies involving 
end of life conversations with heart failure patients found that while conversations of 
disease management are pervasive, end of life conversations do not take place and 
health care providers are not comfortable with discussing disease prognosis (64). A 
survey of caretakers of patients with heart disease found that 63% were not aware of 
the prognosis of the disease, and demonstrated limited understanding of the risk of 
sudden cardiac death (65). These studies show that patients could benefit from 
palliative care services, such as better communications about disease trajectory and 
prognosis as well goals of care conversations to help patients make informed 
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Study Aims and Hypotheses  
Notably lacking from our current understanding of heart failure is the 
prevalence and natural history of a comprehensive range of symptoms during and 
after heart failure hospitalization. Residual symptoms are known to be a powerful 
driver of recurrent health care utilization and therefore costs after hospitalization for 
heart failure (66). Intensive symptom management and integration of palliative care 
into the routine management of decompensated heart failure may therefore represent a 
promising approach to improve outcomes after heart failure hospitalization. However, 
heart failure patients’ preferences regarding use of palliative care have not been 
described previously. Therefore, our objectives in this study were to evaluate 
symptom burden among patients during heart failure hospitalization and immediately 
post-discharge, assess the change in symptoms experienced by patients, from time of 
admission to one week post-discharge, and to evaluate patients’ knowledge and 
perception of palliative care.  
 
Hypothesis 1: Patients discharged from the hospital after an episode of acute 
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Hypothesis 2: Patients discharged from the hospital after an episode of acute 
decompensated heart failure will frequently demonstrate a lack of improvement of 
troublesome symptoms.  
 
Hypothesis 3:  Patients admitted to the hospital for acute decompensated heart failure 
will demonstrate a lack of understanding of the potential role of palliative care in 




This was a prospective cohort study in which patients hospitalized for 
decompensated heart failure at Yale-New Haven Hospital were enrolled from August 
2013 through November 2014. Potentially eligible participants were 18 years of age 
or older and were identified by screening the electronic medical record for an 
admission diagnosis heart failure. Diagnosis of decompensated heart failure was 
confirmed by clinical signs and symptoms (paroxysmal nocturnal dyspnea, neck vein 
distention, rales, S3 gallop, increased central venous pressure, hepatojugular reflux, 
weight loss  >4.5 kg in 5 days in response to treatment, bilateral ankle edema, 
nocturnal cough, dyspnea on ordinary exertion, hepatomegaly, decrease in vital 
capacity by one third from maximum recorded, and tachycardia) and chest 
radiographic findings (acute pulmonary edema, cardiomegaly and pleural effusion) 
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based on the Framingham Criteria (67). Exclusion criteria included hemodynamic 
instability requiring admission to intensive care unit or cardiac/coronary care unit, 
non-English speaking, decisional impairment compromising informed consent based 
on the University of California, San Diego Brief Assessment of Capacity (UBACC) 
documented dementia in electronic medical record, surgery for valve replacement 
during index hospitalization, active malignancy and ongoing hemodialysis (as 
symptom management in these patients is likely to be different from general heart 
failure populations). The San Diego Brief Assessment of Capacity is a validated tool 
for assessing decision making capacity for participating in clinical research (68) and 
was administered when the primary care team could not confirm the decisional 
capacity for informed consent.  
 
Data Collection 
Patients were approached for enrollment within two days of admission for 
decompensated heart failure. After a thorough explanation about the study and 
obtaining consent, patients were interviewed about their symptom burden using 
standardized survey tools (Edmonton Symptom Assessment Scale and Patient Health 
Questionnaire) and queried about symptom presentation and perception (see 
‘Symptom Assessment’). Patients were also queried about their knowledge of 
palliative care during their hospital admission (“baseline interview”). A follow-up 
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telephone interview was conducted seven to ten days after hospital discharge to assess 
perception of symptoms and symptom burden using the same standardized surveys.  
Data Measures 
Socio-Demographics 
Socio-demographic information collected from the patient interview included 
gender, race, ethnicity, education level, marital status and living situation. Patients 
were also asked about smoking history and alcohol use. 
 
Clinical  
The severity of heart failure was assessed using the New York Heart 
Association (NYHA) Functional Classification. This commonly used system places 
patients in one of four categories depending on physical limitation and symptom 
burden. NYHA class I patients do not have limitations of physical activity and do not 
exhibit symptoms with normal activity. NYHA class II is characterized by slight 
limitation of physical activity and mild symptoms. NYHA class III is characterized 
by marked limitations in activity and symptoms with less than ordinary exertion. 
NYHA class IV is characterized by severe limitation in physical activity and 
symptoms at rest (69). The NYHA class was initially assessed during the patient 
interview and then verified with the history and physical exam note from the inpatient 
cardiology team.  
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The electronic medical record was reviewed for age, BMI, last recorded 
ejection fraction, comorbid conditions, medications at discharge, length of hospital 
stay, medications at discharge and discharge location.  
 
Symptom Assessment  
We assessed symptoms using the Edmonton Symptom Assessment Scale 
(ESAS), a standardized questionnaire first described in 1991 to assess symptoms for 
patients in a palliative care unit (70). It was validated in cancer patients (71, 72) and 
has since been validated in heart failure populations by comparison with accepted 
heart failure tools such as Kansas City Cardiomyopathy Questionnaire (KCCQ) (23, 
73, 74). The questionnaire assesses presence and severity of nine symptoms: pain, 
fatigue, drowsiness, nausea, lack of appetite, shortness of breath, depression, anxiety 
and wellbeing using a visual analog scale (a 100-mm line with labels at 0 through 
10). One blank scale (“other problem”) is included in the survey to capture other 
symptoms, which we used to collect information about “edema”.  
Patients were first given an explanation of the scale used in ESAS, and were 
given a blank questionnaire to allow for visualization of the scale. For standardization 
of results, the student researcher administered the survey to all patients. Patients were 
asked to rate the severity of the aforementioned symptoms at the time of the interview 
on a scale of 0 to 10, where 0 denotes absence of the symptom and 10 denotes worst 
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possible severity. ESAS also provides an outline of the body to denote location of 
pain, which was eliminated from this study.  
The Patient Health Questionnaire (PHQ-8), a widely used and well-validated 
screening tool, (75, 76) was utilized to screen for depression. The PHQ-8 is 
comprised of eight out of the nine DSM-IV criteria for diagnosis of depression, and a 
score of 10 or greater is defined as current depression. A large survey of 198,678 
participants found no statistical difference in the prevalence of depression when 
defined by the DSM-IV algorithm or with a score of 10 or greater on PHQ-8 (76). 
The questionnaire is also a reliable and valid tool in patients with heart failure (77).  
During the baseline interview, patients were asked to identify the symptoms 
that triggered the visit to the hospital (see Figure 1). 
Figure 1: Presenting Symptoms 
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This information was utilized in the follow up telephone interview when 
patients were then queried about their perception of the presenting symptoms (Figure 
2). When administering the survey, the surveyor filled in the ‘blank space’ with 
symptoms the patient had reported during the baseline interview (Figure 1). 
 
Figure 2: Perception of Presenting Symptoms  
 
 
Patients’ Knowledge and Perceptions about Palliative Care  
Patients were also queried about their existing knowledge of palliative care 
with the following list of questions. These questions were based on input from experts 
in health services research and palliative care. The questionnaire included whether 
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patients had heard of the term ‘palliative care,’ what services they thought palliative 
care provides, and who benefits the most from palliative care. 
 
 
All patients received a brief, standardized explanation of the goals of palliative care 
with the following script, and were then queried about their interest in receiving 
palliative care services while hospitalized and at home after discharge. 
For patients who had heard of ‘palliative care’… 
1) What kind of services does palliative care provide? 
2) Who do you see as benefiting the most from palliative care? 
3) Are you interested in receiving palliative care while in the hospital? 
4) Do you think palliative care could help you feel better in the hospital? 
5) Do you think palliative care could help you feel better at home?  
For patients who had not heart of ‘palliative care’… 
1) Do you think you would be interested in seeing a healthcare provider who 
specializes in symptom management? 
2) Would you like to see this provider while hospitalized?  
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“As you may already know, congestive heart failure means that your heart is 
not able to pump blood as well, which causes some of the symptoms that 
you experience such as shortness of breath. The traditional treatment for 
when you come into the hospital is to get rid of the fluid build up, however, 
some of the symptoms that you experience, such as pain and fatigue, have 
many different causes. Palliative care is a holistic approach, meaning 
providers look at the patient as a whole rather than just focusing on ‘fixing 
the heart.’ Palliative care is specialized care by trained doctors and nurses to 
provide coordinated care, focusing on symptom management and 
communication to improve quality of life for both you and your family. It is 
an additional layer of support with the care you are already receiving in the 
hospital to address all the symptoms you are currently having. It is not the 
same as hospice or end of life care. For example, if you are experiencing 
pain, palliative care specialists will help you feel better using both pain 
medications and other approaches. As you may already know, your 
hospitalizations for heart failure are unpredictable, and palliative care 
specialists can help you plan for the next time this happens, to address what 
you want and what your goals are care are.” 
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Statistical Analysis   
Baseline characteristics were calculated as percentages for categorical 
variables (i.e. gender, race etc.) and as means with standard deviations for continuous 
variables (i.e. BMI, BP, etc.). Prevalence was calculated for each symptom on ESAS 
by dividing the total number of patients who reported a symptom score of ≥ 1 by the 
total number of patients. Mean values (with standard deviation) were calculated for 
each of the nine symptoms on the ESAS questionnaire. P values were calculated 
using paired t-test to compare symptoms between the baseline and follow up groups. 
A p-value of <. 05 was considered statistically significant.  
Data was entered into an Excel database twice, with a function set to detect 
mismatch and errors, to ensure accuracy of data entry. Data was analyzed using 
Microsoft Excel Version 14.0.0 and GraphPad Prism Version 6.0d. The study was 
reviewed and approved by the Yale University Human Investigation Committee. All 
patients signed a written informed consent prior to participation. 
 
Role of the Student in Research Project 
Under the guidance of research advisor, the student prepared the Institutional 
Review Board (IRB) protocol, designed the data collection forms and Excel database, 
developed a system within the electronic medical record system for real-time 
identification of patients, screened, consented and enrolled patients in the study, 
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conducted all baseline and follow up interviews, entered data into an Excel database, 




Patient Characteristics  
We approached 121 patients for enrollment, 91 consented and were enrolled 
in the study. The mean time of the baseline interview was day 2.5 (SD 1.6) of 
hospitalization, and the median time of the baseline interview was day 2.0 of 
hospitalization. The mean length of stay was 8.9 days (SD 6.6 days) and the median 
length of stay was 6.0 days. Four patients were lost to follow up, and two patients 
died during the index hospitalization from cardiac arrest. The mean time for the 
follow-up interview was 9.9 days (SD 4.3 days) after hospital discharge; 89.9%% 
were interviewed within 2 weeks of discharge.  
The baseline characteristics of these 91 patients are listed in Table 2. Their 
mean age was 71.5 (SD 12.6) years, 65.9% were 65 years of age or older, 51.6% 
were female, 74.7% had an ejection fraction < 50 and 74.7% had NYHA class III or 
IV heart failure.  The most common comorbidities were hypertension (75.8%), 
hyperlipidemia (65.9%), and coronary artery disease (60.4%).  
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Table 1: Baseline Characteristics   
Age, mean (SD) 71.5 (12.6) 
Female, n (%) 47 (51.6%) 
Nonwhite race, n (%) 22 (24.2%) 
Marital status, n (%)  
     Married 40 (44.0%) 
     Other  51 (56.0%) 
Lives alone, n (%) 22 (24.2%) 
Education level, n (%)  
     <High school degree 6 (6.6%) 
     High school graduate 43 (47.3%) 
     College and higher  42 (46.2%) 
History of smoking, n (%)  54 (59.3%) 
Current alcohol Use, n (%) 27 (29.7%)  
BMI, mean (SD) 33.0 (10.1) 
     BMI > 30 42 (46.2%) 
Blood pressure, mean (SD)  
     Systolic 133.6 (26.2) 
     Diastolic  75.9 (20.5) 
Left ventricular ejection fraction, n (%)  
     LVEF <40% 56 (61.5%) 
     LVEF >40% 35 (38.5%) 
Comorbid conditions, n (%)   
    Hypertension  69 (75.8%) 
    Hyperlipidemia  60 (65.9%) 
    Coronary artery disease  55 (60.4%) 
    Diabetes 41 (45.1%) 
    Chronic kidney disease 29 (31.9%) 
    Chronic lung disease 24 (26.4%) 
NYHA Class, n (%)  
     I 1 (1.1%) 
     II 22 (24.2%) 
     III 51 (56.0%) 
     IV 17 (18.7%) 
Length of stay, mean days (SD)  8.9 (6.6 days) 
Discharge medications, n (%)  
     Loop diuretic  84 (93.4%) 
     ACE inhibitor, angiotensin II receptor blocker 34 (37.4%) 
	  








Edmonton Symptom Assessment Scale  
Figure 3 illustrates the prevalence of symptoms during the baseline interview 
as compared to the follow-up interview. The most frequent symptoms reported during 
the baseline interview based on ESAS were decreased wellbeing (80 patients, 
94.1%), fatigue (73 patients, 85.9%) and shortness of breath (69 patients, 81.2%). 
There was a high prevalence of other symptoms not commonly associated with heart 
failure, such as anxiety and pain. Anxiety was reported by 53 patients (62.4%) and 
pain was reported by 40 patients (47.1%). The least prevalent symptom was nausea 
(10 patients, 11.8%). 
The most frequent symptoms reported in the follow-up interview were also 
decreased wellbeing (81 patients, 95.3%), fatigue (75 patients, 88.2%) and shortness 
of breath (72 patients, 84.7%). Anxiety was reported by 51, or 60.0% of patients and 
pain was reported by 55.3% of patients in the follow up interview. The least prevalent 
symptom was nausea (3 patients, 3.5%).  
     B-blocker 75 (82.4%) 
     Aldosterone receptor antagonist  24 (26.4%) 
     Digoxin 5 (5.5%) 
Disposition, n (%)  
     Home 59 (64.8%) 
     Short term rehabilitation  29 (31.9%) 
     Other  3 (3.3%) 
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Figure 3: Symptom Prevalence  
    
 
 
Tables 2 lists the prevalence and mean scores from the ESAS scale for both 
the baseline and follow-up interview. The most severe symptoms during the baseline 
interview were decreased wellbeing (mean score 5.18, SD 2.4, p<. 0001), fatigue 
(mean score 4.99, SD 2.8, p<. 0001) and shortness of breath (mean score 4.74, SD 
3.1, p<. 0001). Anxiety was reported with a mean score of 3.36 (SD 3.3, p<. 0001) 
and pain was reported with a mean score of 2.42 (SD 3.0, p<. 0001) during the 
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The most severe symptoms in the follow-up interview were fatigue (mean 
score 4.93, SD 2.8, p<. 0001), decreased wellbeing (mean score 4.52, SD 1.9, p<. 
0001), and shortness of breath (mean score 4.00, SD 2.4, p<. 0001). Anxiety was 
reported with a mean score of 3.01 (SD 3.1, p<. 0001) and pain was reported with a 
mean score of 2.84 (SD 3.0, p<. 0001). 
While symptoms persisted post discharge (p<. 0001), the mean scores for 
nausea, lack of appetite, shortness of breath, depression, wellbeing and edema 
decreased in the follow up interview as compared to the baseline interview (p<. 05, 
Table 2). In contrast, the mean scores for pain, fatigue, drowsiness and anxiety did 
not show a significant change from the baseline interview to the follow up interview 
(p>.05).  
 
Table 2: Edmonton Symptom Assessment Scale  
 Baseline Interview Follow-up Interview  
Symptom  Prevalence (%) Mean score 
(SD) 
Prevalence (%) Mean score (SD) P-value 
Pain 40 (47.1%) 2.42 (3.0) 47 (55.3%) 2.84 (3.0) 0.2135 
Fatigue 73 (85.9%) 4.99 (2.8) 75 (88.2%) 4.93 (2.8) 0.8578 
Drowsiness 63 (74.1%) 4.28 (3.3) 62 (72.9%) 3.79 (3.0) 0.1857 
Nausea 10 (11.8%) 0.67 (2.1) 3 (3.5%) 0.14 (0.8) 0.0353 
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Lack of appetite  40 (47.1%) 2.45 (2.9) 36 (42.4%) 1.79 (2.4) 0.0194 
Shortness of 
breath  
69 (81.2%) 4.74 (3.1) 72 (84.7%) 4.00 (2.4) 0.0284 
Depression 41 (48.2%) 2.76 (3.2) 32 (37.6%) 1.96 (3.0) 0.0153 
Anxiety  53 (62.4%) 3.36 (3.3) 51 (60.0%) 3.01 (3.1) 0.2546 
Decreased 
Wellbeing  
80 (94.1%) 5.18 (2.4) 81(95.3%) 4.52 (1.9) 0.0183 
Other: Edema  60 (70.6%) 4.09 (3.4) 46 (54.1%) 2.24 (2.5) < 0.0001 
 
 
Figure 4 illustrates the proportion of patients who did not report improvement 
in symptoms in the follow-up interview as compared to the baseline interview. Forty-
nine patients (57.6%) reported the same or increased level of fatigue (p<. 0001) and 
forty-five patients (52.9%) did not report increased overall wellbeing (p<. 0001). 
Thirty-six patients (42.4%) reported the same or increased level of shortness of 
breath (p<. 0001). Thirty-five patients (41.2%) reported the same or increased level 
of pain (p<. 0001) and thirty-five (41.2%) of patients reported the same or increased 
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Figure 4: Proportion of Patients Who Did Reported No Improvement in Symptoms 
   
 
 
Patient Health Questionnaire 
Figure 5 illustrates the distribution of the scores on the baseline and follow-up 
PHQ-8. Fifty-one (60.0%) patients scored >10 on the PHQ-8 during the baseline 
interview and met the criteria for current depression. Thirty (35.3%) of patients 
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Figure 5: Patient Health Questionnaire-8  
    
 
 
Perception of Presenting Symptoms 
Table 3 lists patients’ perception of their symptoms during the follow up 
interview (please see Figure 1 and 2 for questionnaire). The majority of patients (52 
or 61.2%) perceived symptoms to have been partially or not at all addressed by the 
healthcare providers during hospitalization, and (47, or 55.3%) perceived their 
symptoms to have only been partially ameliorated at time of discharge. Twenty-four 
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Table 3: Perception of Symptoms 
 Completely, n (%)  Partially, n (%) Not at all, n (%) 
Did your (symptoms) get better by 
the time you were discharged? 
32 (37.7%) 47 (55.3%) 6 (7.1%) 
Were your symptoms adequately 
addressed by healthcare providers 
during your hospitalization? 
51 (60.00%) 41 (48.2%) 11 (12.9%) 
Have your symptoms affected your 
day-to-day activities? 
24 (28.2%) 47 (54.1%) 14 (16.5%) 
 
Perception of Palliative Care 
Nineteen patients (22.4%) out of 85 had heard of the term “palliative care.” 
Of these patients, fourteen (73.7%) were interested in receiving palliative care 
services in the hospital. Shown in Table 4 are quotes illustrating patients’ 
perspectives of palliative care. Sixty-six patients (77.6%) had not heard of the term 
“palliative care.” After a brief, standardized explanation of what palliative services 
are designed to do (see Methods), forty-four (51.8%) were interested in receiving 
palliative care services while hospitalized. Twenty-two patients (25.9%) were 
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Table 4: Perceptions of Palliative Care  
“Takes care of very ill patients and make them comfortable” 
“Visiting nurse, home care” 
“Home care for elderly and sick” 
“Pain relieve, patient comfort, support for family” 
“The kind to help support people who aren’t feeling well” 
“Helping patients get along and cope with symptoms” 
“Comfort to dying patient and family, relieve family from care” 
“Help with day to day activities, not in hospital setting’’ 
“Keeping people comfortable as they end their lives” 
“Outpatient basic services that help with day to day care” 
“Useful for older people at end of life when they need lots of medical care” 
“For cancer patients in extreme pain” 
“For dying patients” 
“The patient who’s departure is eminent” 
“Semi-holistic teach approach to care”  
“Comfort care” 
“When someone comes in and helps make decisions” 
“Visiting nurse who gives medications”  
“Hospice care when end is coming” 
“Nurses coming in to help at home” 
“Hospice care right before people die” 
“Team effort towards the patient to provide everything the patient needs” 
“Helps cancer patients” 
“Scientific care combined with nontraditional care” 
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Discussion 
We found that patients hospitalized for heart failure experience a high burden 
of symptoms during hospitalization and shortly after discharge. These symptoms 
include not only those classically associated with heart failure such as dyspnea and 
edema, but also anxiety, pain and depression. Symptoms often persisted after hospital 
discharge despite intensive inpatient treatment for heart failure. Furthermore, while 
there was improvement in shortness of breath, depression, nausea, lack of appetite, 
edema and overall wellbeing, patients did not report a significant change in symptoms 
of pain, fatigue, drowsiness and anxiety after hospital. The majority of patients 
surveyed perceived that their presenting symptoms did not get better by time of 
discharge, and that presenting symptoms effected daily activities shortly after 
discharge. We also found that the majority of patients were unfamiliar with palliative 
care. Patients who had heard of palliative care often were not able to demonstrate a 
complete or accurate understanding of its meaning or implications. 
There are relatively few studies evaluating symptom burden during and after 
hospitalization. The Pain Assessment, Incidence & Nature in Heart Failure study, 
which evaluated pain in 347 outpatients with advanced heart failure, reported pain in 
84% of patients (78). Another recent study which evaluated symptom burden in 100 
patients hospitalized for heart failure found that 60% of patients reported pain; 
decreased well-being (95%), fatigue (94%), and shortness of breath (91%) were the 
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most commonly reported symptoms during an acute heart failure decompensations 
(24). Notably, this study did not follow patients after hospital discharge to assess 
change in symptom burden or severity. One study (n=62) evaluating the prevalence 
and severity of pain in the outpatient setting found that 52% of patients reported pain 
(mean pain score of 2.5 ± 3.1), with higher pain scores correlated with lower EF 
(29). Several other studies have demonstrated symptom burden using various 
questionnaires (30, 79-83). However, to our knowledge, this is the only study that 
includes a longitudinal assessment of symptom burden during heart failure 
hospitalizations and shortly after discharge. While there are studies demonstrating 
limited knowledge of palliative care among clinicians (46, 55), there has been little 
prior work on perceptions of palliative care in the heart failure population. 
The high symptom burden immediately after heart failure hospital discharge, 
as well as patients’ perception that presenting symptoms did not get improve by time 
of discharge, suggests that our current approach to decompensated heart failure does 
not adequately address patients’ symptoms. There are many potential reasons for the 
inadequacy. First, the existence of multiple comorbid medical conditions is common 
in the aging heart failure population, and these comorbidities may be contributing to 
symptoms. Dyspnea and fatigue may arise not just from decreased cardiac output and 
pulmonary congestion but rather from a combination of systemic effects of heart 
failure, as well as impact from comorbid conditions such as depression and obesity 
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(23, 37, 84, 85). Patients with severe kyphosis or COPD may have residual dyspnea 
even after euvolemia is achieved (23, 37, 84, 85). Sleep related breathing 
abnormalities causing oxygen desaturation stimulating sympathetic drive may 
increase daytime fatigue (86). Hormonal changes and pro-inflammatory cytokine 
releases in heart failure result in a catabolic state (87) (i.e., increased insulin 
resistance), muscle remodeling, and respiratory and skeletal muscle atrophy and 
weakness (23, 88).  
Second, clinicians caring for patients hospitalized for heart failure may not be 
prepared to thoroughly assess and treatment symptoms such as pain, anxiety, 
depression, and fatigue (38). For example, pain may be undertreated since traditional 
therapies such as nonsteroidal anti-inflammatory drugs are avoided in heart failure as 
they can cause renal damage (89). Finally, there is growing pressure on health 
systems to reduce length of stay and once patients no longer meet criteria for 
hospitalization (such as requiring supplemental oxygen or intravenous diuretics) there 
is an impetus to discharge them even if they have remaining symptoms.  These 
residual symptoms may by driving health care utilization (23, 90, 91). 
We found that symptoms of pain, anxiety, fatigue, and drowsiness did not 
improve after hospital discharge. Unlike alleviations of symptoms of shortness of 
breath and edema that are goals of hospital admissions, these symptoms may not be 
targeted by traditional heart failure therapy. The etiology of pain in heart failure is not 
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clearly understood and most likely multifactorial in etiology, and treatment is difficult 
without full understanding of mechanism.  
The progressive nature of heart failure, coupled with high mortality rates and 
poor quality of life, makes it ideally suited for the incorporation of palliative care. 
There have been numerous calls to include palliative care as a component of heart 
failure management, including from the American Heart Association, but fewer than 
10% of patients with heart failure receive palliative care (44, 45). We found that the 
majority of patients had not heard of palliative care, and those who had heard of the 
term were not able to articulate a complete understanding. The gap in patient 
knowledge base may be because palliative care is underutilized and not a standard of 
care in the heart failure population. Obstacles to integrating palliative care into heart 
failure may include a prevailing and untrue perception among both clinicians and care 
providers that palliative care and life-prolonging therapies are mutually exclusive, the 
belief that heart failure is a chronic and manageable illness, unpredictable trajectory 
of heart failure, a shortage of specialty-trained palliative care clinicians, and a lack of 
training for cardiology clinicians in the basic elements of palliative care (23, 24, 42, 
92, 93).  
Patients with heart failure have an unpredictable trajectory and variable 
prognosis. Their course is marked by exacerbations characterized by a rapid decline 
in function; with appropriate treatments some may improve clinically, although the 
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overall course remains a downward trajectory (52, 53). Because it is not clear which 
exacerbation will lead to death, earlier integration of palliative care is important.  
Furthermore, patients and families are often not aware of poor prognosis that heart 
failure carries (94).  Early integration of palliative care can lead to open 
communication about goals of care, helping patients understand their disease and 
make informed decisions.  
In addition to improving patient care, integration of palliative care has the 
potential to decrease healthcare costs. Eighty-four percent of the total healthcare 
spending is on chronic conditions which includes heart failure (95).  As a tertiary 
prevention measure, integration of palliative care can decrease readmissions. It can 
also decrease healthcare costs by decreasing the length of stay in hospital and number 
of interventions performed near end of life, the length of stay. A large multi-hospital 
system based study demonstrated that inpatient palliative care resulted in $279 to 
$374 in direct cost savings per day (96). To date, there are limited interventional 
studies evaluating the effects of implementation of palliative care in the heart failure 
population. One small interventional study (n=36) found that heart failure patients 
reported greater symptom control after three months of outpatient based palliative 
care following an acute decompensation (83), consistent with other studies (97). 
Larger trials are needed to evaluate what barriers exist to integrating palliative care in 
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routine care, and whether palliative care will be effective in reducing symptom 
burden and outcomes (i.e., readmission and healthcare costs). 
 
Study Limitations 
There are several limitations to our study. First, this is single system study 
with a small sample size, and thus it is possible that the results are not generalizable 
to the population as a whole. However, Yale-New Haven Hospital is the fourth 
largest hospital system in the nation and demographics are comparable to national 
averages (98).  Second, patients’ description and experience of symptoms may 
fluctuate with time but symptoms were assessed at two points, the baseline and 
discharge interview. Furthermore, there was variation between patients in terms of 
when the baseline and follow up interviews were conducted. For example, some 
patients were interviewed immediately after admission before initiation of treatment, 
and their reported symptom burden could have been higher at baseline than if the 
baseline interview was conducted closer to discharge. However, the mean time of the 
baseline interview was day 2.5 (SD 1.6) of hospitalization whereas the mean length 
of stay was 8.9 days (SD 6.6 days). The utilization of the Edmonton Symptom 
Assessment System helps in standardizing the quantification of symptom burden. 
Importantly, we do not have data on treatment for symptoms (i.e., pain medication 
prescribed during or after hospitalization). Therefore, we cannot comment on 
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adequacy of treatment for symptoms, only on presence and severity of symptoms 
during and after hospitalization. 
 
Conclusion  
Patients hospitalized for heart failure experience a high burden of symptoms, 
including not just dyspnea and fatigue but also anxiety and pain. These symptoms are 
common during hospitalization, but the majority of patients experience troublesome 
symptoms shortly after discharge as well. Given that symptoms frequently drive 
health care utilization, early integration of palliative care into routine heart failure 
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